Jiangsu Hengrui’s PD-1 inhibitor flashes potential in treating liver cancer
Jiangsu Hengrui Medicine, which won approval for its PD-1 treatment for Hodgkin lymphoma last year, is now trying to build its case for using the therapy to treat liver tumors, among a basket of other cancers it is pursuing.
Last week, The Lancet Oncology published data from the company’s Phase 2 trial of camrelizumab, which enrolled over 200 patients with advanced hepatocellular carcinoma (HCC) who had failed or couldn’t tolerate previous systemic treatment. About 15% of patients saw their tumors shrink and the overall survival probability was 74% after six months, though two patients did die from potentially treatment-related causes.
The race for the HCC indication is pretty packed – other contestants include Beigene’s tislelizumab (百泽安), AstraZeneca’s durvalumab (Imfinzi), Junshi Biosciences’ toripalimab (Tuoyi) and Innovent Biologic’s sintilimab (Tyvyt).
Last week, The Lancet Oncology published data from the company’s Phase 2 trial of camrelizumab, which enrolled over 200 patients with advanced hepatocellular carcinoma (HCC) who had failed or couldn’t tolerate previous systemic treatment. About 15% of patients saw their tumors shrink and the overall survival probability was 74% after six months, though two patients did die from potentially treatment-related causes.
The race for the HCC indication is pretty packed – other contestants include Beigene’s tislelizumab (百泽安), AstraZeneca’s durvalumab (Imfinzi), Junshi Biosciences’ toripalimab (Tuoyi) and Innovent Biologic’s sintilimab (Tyvyt).
.png)
No hay comentarios:
Publicar un comentario